BMP-7 Induced Islet-Like Cell Clusters for Type 1 Diabetes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for treating type 1 diabetes, such as islet transplantation, are limited by the scarcity of donor pancreata and the need for genetic manipulation, which poses regulatory and safety challenges.

Innovation Solution

Exposure of human non-endocrine pancreatic tissue to Bone Morphogenetic Protein 7 (BMP-7) to induce the formation of islet-like cell clusters, which can be transplanted to treat insulin-deficiency disorders, offering a non-genetic conversion of adult pancreatic tissue into insulin-producing cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If islet transplantation is used to treat type 1 diabetes, then insulin production is restored, but donor pancreata scarcity limits clinical application

Engineering Contradiction:

Improveinsulin production restorationVSAvoiddonor pancreata availability

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patient's own non-endocrine pancreatic tissue is converted into insulin-producing cells through BMP-7 treatment, eliminating the need for donor organs. The body's existing tissue serves its own therapeutic purpose by being reprogrammed in situ or ex vivo and transplanted back.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

BMP-7 treatment induces a fundamental change in cell differentiation parameters, causing non-endocrine pancreatic cells to transform into endocrine insulin-producing cells. This parameter change in cell fate enables unlimited source material from the patient's own pancreas.

Inventive Principle:

Principle #35Parameter changes

2Productivity

If genetic manipulation methods are used to convert pancreatic tissue, then insulin-producing cells can be generated, but regulatory and safety challenges arise

Engineering Contradiction:

Improveinsulin-producing cell generationVSAvoidregulatory and safety risks

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces complex genetic manipulation mechanisms with a simpler protein-based signaling approach. Instead of introducing foreign genes or using viral vectors, BMP-7 protein naturally activates endogenous signaling pathways to induce cell differentiation, eliminating genomic integration risks.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

BMP-7 acts as a safe intermediary molecule that mediates the conversion process without requiring direct genetic manipulation. The protein serves as a controllable, reversible signal that guides cell differentiation through natural biochemical pathways rather than permanent genetic changes.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Quantity of substance

If non-endocrine pancreatic tissue is converted to endocrine cells, then islet donor shortage is overcome, but the conversion process complexity increases

Engineering Contradiction:

Improveavailable pancreatic tissue for conversionVSAvoidconversion process complexity

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the key differentiating factor (BMP-7 protein) from complex developmental processes. By identifying and applying this single critical factor, the complex natural differentiation process is simplified into a controllable ex vivo treatment protocol.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

Non-endocrine pancreatic tissue is pre-treated with BMP-7 in vitro before transplantation, allowing the conversion process to occur under controlled conditions. This preliminary action ensures complete differentiation before implantation, simplifying the overall therapeutic procedure.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach generates functional insulin-producing cells that are glucose-responsive and can effectively treat insulin-deficiency disorders, potentially overcoming the limitations of existing treatments by using a FDA-approved compound to activate progenitor cells within the exocrine compartment of the pancreas.

Implementation Method 1

Exposure of human non-endocrine pancreatic tissue to Bone Morphogenetic Protein 7 (BMP-7) to induce the formation of islet-like cell clusters

Methodology Applied

Scientific EffectBone Morphogenetic Protein signaling:

Data Source

PatentUS11466255B2Methods and compositions for converting non-endocrine pancreatic tissue into insulin-producing cells

Publication Date: 2022.10.11 UNIV OF MIAMI

AI summary

Compositions and methods are provided for generating islet-like cell clusters. The methods include culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having Bone Morphogenetic Protein (BMP) activity (e.g., a BMP polypeptide). The effective amount of said molecule having BMP activity (e.g., BMP polypeptide) is sufficient to induce the formation of islet-like cell clusters. The methods further include treating or attenuating insulin-deficiency disorders, including type 1 diabetes. In one non-limiting embodiment, an insulin-deficiency disorder in a subject is treated or attenuated by culturing a whole non-islet pancreatic cell discard or cells sorted therefrom with an effective amount of a molecule having BMP activity (e.g., a BMP polypeptide) such that tho formation of islet-like cell clusters occurs. A therapeutically effective amount of the islet-like cell clusters which produce insulin are then transplanted into a subject in need to treat the insulin-deficiency disorder.